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Abstract
Background: Charcot neuropathic arthropathy (CN) is a chronic, progressive, destructive, non-infectious process
that most frequently affects the bone architecture of the foot in patients with sensory neuropathy. We evaluated
the outcome of protected weightbearing treatment of CN in unilaterally and bilaterally affected patients and
secondarily compared outcomes in protected versus unprotected weightbearing treatment.
Methods: Patient records and radiographs from 2002 to 2012 were retrospectively analyzed. Patients with Type 1
or Type 2 diabetes with peripheral neuropathy were included. Exclusion criteria included immunosuppressive or
osteoactive medication and the presence of bone tumors. Ninety patients (101 ft), mean age 60.7 ± 10.6 years at
first diagnosis of CN, were identified. Protected weightbearing treatment was achieved by total contact cast or
custom-made orthosis. Ulcer, infection, CN recurrence, and amputation rates were recorded. Mean follow-up was 48
(range 1–208) months.
Results: Per the Eichenholtz classification, 9 ft were prodromal, 61 in stage 1 (development), 21 in stage 2
(coalescence) and 10 in stage 3 (reconstruction). Duration of protected weightbearing was 20 ± 21 weeks and 22 ±
29 weeks in patients with unilateral and bilateral CN, respectively. In bilaterally affected patients, new ulcers
developed in 9/22 (41%) feet. In unilaterally affected patients, new ulcers developed in 5/66 (8%) protected
weightbearing feet and 4/13 (31%) unprotected, full weightbearing feet (p = 0.036). The ulceration rate was
significantly higher in bilaterally versus unilaterally affected patients with a protected weightbearing regimen (p = 0.
004). Soft tissue infection occurred in 1/13 (8%) unprotected weightbearing feet and 1/66 (2%) protected
weightbearing feet in unilaterally affected patients, and in 1/22 (4%) protected weightbearing feet of bilaterally
affected patients. Recurrence and amputation rates were similar across treatment modalities.
Conclusions: Bilateral CN results in significantly more ulcers than unilateral CN and leads to slightly higher soft
tissue infections. Protected weightbearing in an orthopedic device can reduce the risk for complications in acute
CN of the foot and ankle.
Keywords: Bilateral, Charcot, Diabetic neuropathic arthropathy, Neuroosteoarthroapthy, Infection, Protected
weightbearing, Total contact cast, Ulcer
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Background
Charcot neuropathic arthropathy (CN) is a chronic, pro-
gressive, destructive, non-infectious process leading to
progressive degeneration of a weightbearing joint. It most
frequently affects the osseous alignment of the foot and
joint alignment in people with sensory neuropathy [1].
The disease was first described in 1868 by Jean-Martin
Charcot in the context of tabes dorsalis [2, 3]. Today, dia-
betes mellitus is the most common cause of peripheral
neuropathy and is therefore often associated with the de-
velopment of CN. From 0.08 to 7.5% of diabetic patients
are diagnosed with CN [4]. With the worldwide increase
in the prevalence of diabetes, diagnosis and treatment of
CN is becoming more important [5].
The main characteristics of CN are atraumatic swelling
with redness and warmth, followed by deformation of the
foot. Often this occurs in only one foot [6]. The exact
pathogenesis of CN is still unclear. However, there are sev-
eral predisposing factors, such as the retention of vasodili-
tatory reflexes of the affected foot, upregulation of
calcitonin gene related peptide and reduction in bone min-
eral density [7–9]. Once the disease has been triggered, it
progresses to an uncontrolled inflammation. The loss of
pain sensation and proprioception combined with repetitive
mechanical trauma to the foot leads to fractures and joint
dislocations [10–12]. Once a bone has fractured, proinflam-
matory cytokines such as tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β) are released, resulting in in-
creased expression of receptor activator of nuclear factor-
kB ligand (RANKL), synthesis of the nuclear transcription
factor NF-κB, and maturation of osteoclasts [8, 13]. Bone
resorption leads to bony destruction, weakening of liga-
ments, and consequent joint destruction secondary to
contributory trauma [14]. Hyperemia through an autonom-
ically stimulated vascular reflex causes additional periarticu-
lar osteopenia [12].
The pathogenesis of CN in the foot differs between pa-
tients with Type 1 and Type 2 diabetes. Petrova et al
found a younger age at onset, a generalized reduction in
bone mineral density, and more severe peripheral neur-
opathy in patients with Type 1 diabetes compared to
those with Type 2 diabetes [15].
The progression of CN follows the stages originally de-
scribed by Eichenholtz [16]. A prodromal inflammation
stage with normal radiographs (Stage 0) is followed by
increasing osseous destruction with radiographic evi-
dence of osseous fragmentation and joint dislocation
(Stage 1, “fragmentation”) and subsequent coalescence
of fragments and absorption of fine bone debris (Stage 2,
“coalescence”). Finally, chronic deformity of the foot
with consolidation and remodeling of fracture fragments
is observed (Stage 3, “reconstruction”).
Charcot neuropathic arthropathy severely reduces the
overall quality of life and dramatically increases the
morbidity and mortality of patients [17, 18]. Evidence-
based guidelines for the treatment of acute CN have yet
to be established. Non-operative treatment to achieve a
plantigrade, stable foot and prevent recurrent ulceration
is regarded as the primary treatment for acute CN feet
[19, 20]. Operative treatment is often reserved for late
complications, such as deep wound infection or osteo-
myelitis [20, 21]. Nevertheless, early reconstructive sur-
gery in patients with an unstable foot with manifest joint
subluxation or radiographic non-plantigrade foot pos-
ition may provide timely restoration of the plantigrade
foot [22]. In particular, unstable deformities in obese
patients are sometimes difficult to brace, and these pa-
tients might benefit from primary corrective arthrodesis
[23, 24]. However, despite satisfactory results, complica-
tion rates following surgery are reported to range from
10% to more than 30% [24, 25].
The aim of the present study was to compare the out-
come of non-operative treatment in patients diagnosed
with unilateral versus bilateral CN. Additionally, we
compared outcomes of protected versus unprotected
weightbearing non-operative treatment and made rec-
ommendations for non-operative therapeutic options.
Methods
Data acquisition
We conducted a retrospective cohort chart review study
at a specialized centre for multidisciplinary treatment of
foot ulcerations and deformities over an eleven-year
period (2002–2012). We conducted a comprehensive
search strategy of our institutional database using the
keywords “Charcot” or “Neuroosteoarthropathy”. Pa-
tients older than 18 years with confirmation of CN by
magnetic resonance imaging (MRI) (i.e., soft tissue
edema, joint effusion, and/or subchondral bone marrow
edema of involved joints, characterized by low signal in-
tensity on T1-weighted images and high signal intensity
on T2-weighted images) at the beginning of treatment
were included in the study. Only patients with a diagno-
sis of Type 1 or Type 2 diabetes with peripheral neur-
opathy recorded in their charts were included.
Individuals treated with immunosuppressive or osteoac-
tive medication (i.e., bisphosphonates) and patients with
osteodestructive bone pathologies, i.e. bone tumors,
were excluded. Patients with diagnosed osteomyelitis or
idiopathic osteoarthropathy were also excluded.
The following data were collected from the patient re-
cords: age, gender, affected limb, duration of diabetes, time
period of protected weightbearing, date of first diagnosis
of CN, recurrence of CN (i.e. new foot deformity and/or
non-infectious swelling and redness), appearance of ulcer
or infection, type of definitive treatment and surgical
intervention for treatment of wounds and infections. This
study was carried out in accordance with our institutional
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ethics committee’s terms of reference. Written informed
consent allowing retrospective data analysis was received
from all patients enrolled in the study.
Patients
A total of 90 patients were identified (age 60.7 ±
10.6 years at first diagnosis of CN), with 101 affected
feet. Eleven patients (12%) had bilateral CN.
The study included 22 (24%) women and 68 (76%)
men, with 28 and 73 affected feet, respectively. Of the
79 unilaterally affected patients, 39 were left feet and 40
were right feet (Table 1).
CN was staged according to the Eichenholtz classifica-
tion [16] by the treating clinician. In unilaterally affected
patients, 6 (8%) were treated in the prodromal period
(stage 0), 49 (61%) demonstrated acute stage 1 CN at the
time of first diagnosis, 16 (21%) were diagnosed and
treated in the coalescence stage 2, and 8 (10%) were
treated for chronic stage 3 CN [16]. In bilaterally
affected patients, 3 ft (14%) were treated in the pro-
dromal period, 12 ft (54%) in the acute stage, 5 ft (23%)
were diagnosed in stage 2, and 2 ft (9%) were diagnosed
in stage 3. Based on Sanders and Frykberg Anatomic
Classification [26], CN was located in the forefoot in
20% of feet, the midfoot in 67% of feet, and the hindfoot
in 13% of feet in unilaterally affected patients (Table 1).
In bilaterally affected patients, CN was located in the
forefoot in 9% of feet and the midfoot in 91% of feet.
Non-operative treatment modalities: protected
weightbearing
Sixty-six unilaterally affected patients were treated with
protected weightbearing. Of these, 57 ft (87%) were ini-
tially supplied with a total contact cast (TCC), consisting
of a properly cushioned, custom-made rigid fiberglass
boot (Fig. 1). Patients were allowed to bear weight as tol-
erated with the aid of two crutches, if needed.
Immobilization consisting of bed rest or limitation in
walking activity was not required. The TCC was followed
by a removable TCC (rTCC) in 20 ft (30%) or a custom-
made orthosis in 11 ft (17%) when symptoms like red-
ness and warmth had decreased sufficiently based on
visual inspection and palpation and no ulcer or infection
Table 1 Baseline patient characteristics
Characteristic Number
Patients (n = 90)
Age at initial diagnosis (years), mean ± SD 60.7 ± 10.6
Follow up period (years), mean ± SD 3.7 ± 3.8
Gender, female/male, n 22/68
Bilateral patients (n = 11) gender:
female/male, n
6/5
Comorbidity, n (%)a
• Diabetes 90 (100)
• Peripheral vascular diseaseb 14 (16)
• Obesity (BMI > 25 kg/m2) 12 (13)
Affected feet (n = 101)
Female/male, n 28/73
Left/right (in unilaterally affected
patients, n = 79), n
39/40
Location of CNc (n = 101 ft)
Zone 1 (distal and proximal interphalangeal
joints, metatarsophalangeal joints)
10 unilateral, 2 bilateral
Zone 2 (tarsometatarsal joints (Lisfranc) 25 unilateral, 10 bilateral
Zone 3 (naviculo-cuneiform joints,
talonavicular joint; cacaneocuboid joint)
8 unilateral, 5 bilateral
Zone 4 (ankle joint, subtalar joint) 3 unilateral, 0 bilateral
Zone 5 (calcaneus) 2 unilateral, 0 bilateral
Zones 1 + 2 6 unilateral, 0 bilateral
Zones 2 + 3 1 unilateral, 0 bilateral
Zones 2 + 4 19 unilateral, 5 bilateral
Zones 3 + 4 3 unilateral, 0 bilateral
Zones 4 + 5 2 unilateral, 0 bilateral
BMI body mass index
aSome patients had multiple comorbidities
bConfirmed with ankle-brachial index (ABI) <0.9
cBased on Sanders and Frykberg Anatomic Classification [26]
Fig. 1 Example of a total contact cast (TCC), consisting of a properly
cushioned, custom-made, rigid, fiberglass boot
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was detected (Table 2, Fig. 2). Cast changes were made
at least every second week by a professionally trained
technician. Patients were seen every three to four weeks
in the outpatient clinic of our institution for follow-up.
Eleven patients were affected bilaterally. Nine patients
received the same initial treatment on both feet: 4 re-
ceived TCCs, 3 received cast shoes, and 2 received or-
thotics (Table 3). The remaining two patients had
different stages of CN in each foot: one patient was
treated with a TCC on one foot and a cast shoe on the
other; the other patient was treated with an orthotic on
one foot and a cast shoe on the other. In the 9 ft that
were supplied with a TCC, this was followed by a rTCC
in 5 ft and a rigid ankle-foot orthosis (AFO) in 1 ft.
Some patients were treated with a cast shoe containing a
custom-made insole because of a lack of compliance and
difficulty with conducting activities of daily living with
two casts.
A rigid AFO (Fig. 3) was used as initial treatment in 6
(9%) unilaterally affected patients and 5 ft of bilaterally
affected patients. It was only used in cases of unstable
foot alignment, or if the patient was unable to come to
the hospital for follow-up.
In patients initially treated with protected weightbear-
ing, definitive treatment was initiated when bony con-
solidation was observed. In cases of minor deformity,
orthopedic shoes were fitted with custom-made insoles
(33 ft (42%) in patients with unilateral CN; 7 ft (32%) in
patients with bilateral CN). In cases of substantial foot
deformity at the reconstruction stage, custom-made
orthopedic shoes were built for 39 ft (49%) of unilat-
erally affected patients and 12 ft (55%) of bilaterally af-
fected patients and an orthosis was built for 5 and 3 ft,
respectively. Following definitive treatment, patients
were seen every six to eight weeks, which was extended
to six-month follow-up intervals with a positive clinical
development.
Unprotected weightbearing
Unprotected weightbearing was defined as orthopedic
shoes with custom-made insoles and custom-made
orthopedic shoes. Thirteen patients (20%) with unilateral
CN refused treatment with a cast and were therefore
supplied with a non-protected regimen. Of these, ortho-
pedic shoes with custom-made insoles were provided for
eight patients, and five patients received a custom-made
orthopedic shoe.
Magnetic resonance imaging was used in all patients
to detect remaining inflammation six months following
non-operative treatment and to rule out deep soft tissue
infections. The incidence of ulcer, infection (i.e., positive
microbiologic culture of a deep wound biopsy), recur-
rence of CN and amputation was recorded in the patient
charts during the follow-up visits.
The mean duration of follow-up was 45 months (range
1–208 months).
Statistical analysis
The start and duration of protected weightbearing, as
well as the type of initial treatment, were determined as
potential factors influencing the appearance of ulcers
and rate of infections, and therefore were considered to
be prognostic factors of the disease. All data from pa-
tient records were exported into an Excel database
(Microsoft Corp, Redmond, WA). For statistical analysis
SPSS 17.0 software (SPSS Inc, Chicago, IL) was used.
For detection of differences between groups, Chi-square
or Fisher’s exact test was conducted. Significance level
was defined as P < 0.05.
Results
Protected weightbearing period
Patients with unilateral CN had a shorter time period
for protected weightbearing treatment (20 ± 21 weeks)
compared to bilaterally affected patients (22 ± 29 weeks).
In patients with unilateral CN, men had a longer period
of protected weightbearing (24 ± 22 weeks) than women
(16 ± 15 weeks), but the difference was not statistically
significant (p = 0.88).
Ulcer and infection
Outcomes following a protected weightbearing treat-
ment regimen were compared in unilaterally and bilat-
erally affected patients. Five of 66 ft (8%) of unilaterally
affected patients developed new ulcers during the treat-
ment protocol. In contrast, in the bilaterally affected
group, 9 of 22 ft (41%) developed new ulcers during the
treatment protocol, indicating a significantly higher inci-
dence of ulceration following a protected weightbearing
in bilaterally affected patients compared to unilaterally
affected patients (p = 0.004) (Table 4).
Table 2 Protected weight-bearing treatment: initial regimen
and cast types used
Cast/Shoe Type Unilaterally affected
feet (n = 66)
N (%)
Bilaterally affected
feet (n = 22)
N (%)
Cast shoe 3 (5) 8 (35)
TCC only 26 (39) 3 (14)
TCC followed by rTCC 20 (30) 5 (23)
TCC followed by 11 (17) 1 (5)
Orthotic/AFO
Orthotic (AFO) 6 (9) 5 (23)
Time to shoes, weeks
(mean ± SD)
20 ± 44 35 ± 28
TCC Total Contact Cast, rTCC removable Total Contact Cast, AFO rigid Ankle
Foot Orthotic
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In patients with unilateral CN (Table 5), new ulcera-
tions developed in 5 of 66 ft (8%) with a protected
weightbearing treatment, compared to 4 of 13 ft (31%)
in patients without a protected weightbearing regimen
(p = 0.036), indicating a significantly higher incidence of
ulceration in an unprotected weightbearing regimen.
Thirteen patients (16%) in the unilaterally affected
group received oral antibiotic treatment for a suggested
soft tissue infection with signs of elevated blood infec-
tion (CRP > 5 mg/l). Blood tests (CRP levels) were only
performed in a clinically suspicious situation, i.e., when a
patient presented with redness and warmth of the foot,
to discriminate infection from active Charcot arthropa-
thy. Seven of 11 patients (64%) with bilateral CN were
treated with prophylactic oral antibiotics for suspected
soft tissue infection in one of their feet (i.e., 7/22 ft;
Feet treated with protected weightbearing
N = 88 feet
66 Unilaterally affected patients
N = 66 feet
11 Bilaterally affected patients
N = 22 feet
Cast 
Shoe
N = 3
Total 
Contact 
Cast
N = 57
Rigid 
Ankle Foot 
Orthotic
N = 6
Followed by
Removable
Total Contact
Cast
N = 20
Followed by
Rigid Ankle 
Foot Orthotic
N = 11
No change
N = 26
Cast 
Shoe
N = 8
Total 
Contact 
Cast
N = 9
Rigid 
Ankle Foot 
Orthotic
N = 5
No change
N = 3
Followed by
Removable
Total Contact
Cast
N = 5
Followed by
Rigid Ankle 
Foot Orthotic
N = 1
Fig. 2 Flow chart of protected weight-bearing treatment regimen (n = 88 ft)
Table 3 Protected weight-bearing treatment regimen in
bilaterally affected patients
Patient Left Foot Right Foot
1 Orthotic (AFO) Orthotic (AFO)
2 Cast shoe Cast shoe
3 TCC followed by removable TCC TCC followed by removable TCC
4 TCC Cast shoe
5 Cast shoe Orthotic (AFO)
6 Cast shoe Cast shoe
7 TCC TCC followed by removable TCC
8 TCC followed by removable TCC TCC followed by orthotic (AFO)
9 Orthotic (AFO) Orthotic (AFO)
10 Cast shoe Cast shoe
11 TCC TCC followed by removable TCC
TCC Total contact cast
Fig. 3 Example of a rigid ankle-foot orthosis (AFO)
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32%). Empiric oral antibiotic therapy was initiated and, if
deep wound biopsies were taken intraoperatively, the pa-
tient was either switched to the precise oral or intraven-
ous antibiotic therapy according to culture results and
sensitivity testing, or therapy was discontinued in the
case of negative culture results.
A total of 60 surgical wound procedures were per-
formed in 50 ft during the follow-up period (Table 6).
Wound debridement was performed for superficial ul-
cerations (n = 47). In the case of deep wound infection,
deep surgical wound treatment with removal of
sequestrum and wound lavage were performed (n = 13).
Osseous prominences causing recurrent ulcerations were
treated by exostosectomy (n = 4). All surgical procedures
were performed by the head of the department for
multidisciplinary treatment of foot ulcerations and foot
deformities, or by an experienced consultant. Although
bilaterally affected patients demonstrated higher rates (5
ft, 23%) of deep surgical wound therapy compared to
unilaterally affected patients (8 ft, 10%), the rates were
not significantly different statistically.
Amputation
Three toe, 1 forefoot (Lisfranc), and 2 below-the-knee
amputations were performed in unilaterally affected pa-
tients, and 4 toe amputations were required in bilaterally
affected patients (Table 4). There were no statistically
significant differences in the rates of amputation or re-
currence of CN for the different treatment modalities.
Discussion
The outcome of non-operative treatment in 90 patients
(101 ft) diagnosed with CN was assessed at a mean
follow-up of 48 months (range 1–208 months). The
average age of patients in our investigation was 60.7
(±10.6) years, which corresponds to previously published
studies [27–29].
Treatment in an orthopedic device, such as a TCC to
minimize mechanical forces on the bone, achieve a
plantigrade, stable foot and prevent recurrent ulceration,
is considered to be an important strategy in acute CN
[6, 24, 27, 30–34]. Yet, there is a wide range of recom-
mendations concerning initial treatment. Some authors
suggest non-weightbearing treatment during the first
months to stop progression of deformity [27, 29, 34, 35].
In particular, they suggest that weightbearing should be
prevented during the inflammation stage, to “cool down
the foot” because of the risk that the unstable foot will
continue to fracture [10, 35]. Frykberg et al recom-
mended a non-weightbearing period of 8–12 weeks to
avoid trauma to the affected foot [34]. Other investiga-
tors allowed weightbearing when the foot was placed in
a cushioned device [10, 36–38]. De Souza et al showed
that protected weightbearing in a TCC does not initiate
new foot ulcers in the treatment of a Charcot foot [10].
Weightbearing does not appear to negatively affect the
outcome in treatment of acute CN, as long as the foot is
protected by a professionally manufactured TCC. Initial
treatment in our institution consisted of a custom-made,
properly cushioned, rigid plaster boot (TCC) or of a
rigid ankle-foot orthosis, with weightbearing allowed as
tolerated. This treatment regimen was associated with a
lower incidence of ulcerations (8%) compared to an un-
protected weightbearing regimen (31%) in patients with
unilateral CN (p = 0.036). Even overweight patients with
stage 1 CN according to Eichenholtz, treated with a
TCC that permitted full weightbearing, successfully pro-
gressed into therapeutic footwear after an average time
Table 4 Outcome parameters in 66 ft of patients with unilateral
CN compared to 22 ft of 11 patients with bilateral CN, following
a protected weightbearing treatment
Unilaterally affected
(n= 66)
Bilaterally affected
(n= 22)
P
Baseline Follow-up Baseline Follow-up
Ulceration, n (%) 16 (24) 21 (32) 4 (18) 13 (59) .004a
- Incidence: 5 (8%) 9 (41%)
Soft tissue infection, n (%) 2 (3) 3 (5) 1 (5) 2 (9)
- Incidence 1 (2%) 1 (4%)
aPearson chi-square/Fisher’s exact test
Table 5 Outcome parameters in unilaterally affected individuals,
stratified by protected weightbearing treatment versus
unprotected, full weightbearing regimen
Protected weightbearing
(n= 66)
Unprotected weightbearing
(n= 13)
P
Baseline Follow-up Baseline Follow-up
Ulceration,
n (%)
16 (24) 21 (32) 2 (15) 6 (46) .036a
- Incidence 5 (8%) 4 (31%)
aPearson chi-square/Fisher’s exact test
Table 6 Surgical procedures performed for wound healing in
79 ft of patients with unilateral CN compared to 22 ft of 11
patients with bilateral CN
Procedure Unilateral CN
(n = 79)
Bilateral CN
(n = 22)
Wound debridement for
superficial ulceration
33 (42%) 14 (64%)
Deep surgical wound treatment
(i.e., removal of sequestrum and
wound lavage)
8 (10%) 5 (23%)
Exostosectomy of osseous prominence 3 (4%) 1 (5%)
Amputation 3 toe 4 toe
1 forefoot (Lisfranc)
2 below the knee
Total: 6 (8%) Total: 4 (18%)
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of 12 weeks [37]. Furthermore, non-weightbearing treat-
ment may have an unfavorable consequence on the
contralateral, unaffected limb in patients with CN, due
to increased stress [30]. Clohisy et al reported that the
time period to affect the contralateral limb is longer
(12 months) in patients with weightbearing treatment
compared to a weight-off regimen (4.5 months) [39]. Our
investigation showed that the incidence of foot ulcers is
higher in bilaterally affected patients compared to unilat-
erally affected individuals (p = 0.004). We therefore rec-
ommend a weightbearing treatment in a TCC in an acute
stage of CN to prevent, or at least defer, progression of the
disease with its complications to the contralateral side.
The alternative to a TCC is a pre-fabricated removable
walker cast (i.e. Aircast®, DJO Global, Cal, USA or
Vacoped®, OPED AG, Cham, Switzerland), which has the
advantage of much lower costs compared to a regularly
changed custom-made TCC. Use of a TCC for diabetic
foot ulcers compared to a removable cast walker or half-
shoe showed higher healing percentages and a shorter
healing time for the TCC [2, 10, 20].
Although a 6% risk for development of pressure ulcers
with the TCC has been reported, the rate of permanent se-
quelae from cast-related injuries is low (0.25%), and the
TCC was rated as a safe modality for protected weightbear-
ing and immobilization of the neuropathic foot [13, 40].
The major disadvantage of a removable, non-custom
tailored device is a diminished compliance due to the
easy removability of the device by the patient [41, 42].
This may lead to increased local pressure on the skin
and, in combination with insensibility, contains an in-
creased risk of ulceration. Compliance with wearing pre-
scribed footwear is low [42, 43]. Only 28% of CN
patients wore their removable walker brace full time
(23.5 h/day), and non-compliance was shown to lead to
a longer bracing period (29 ± 19 weeks) [43]. An import-
ant attribute of the TCC is that it is not easily removable
and therefore has the advantage to enhance compliance
[41]. It also seems to curtail activity, which reduces the
number of stress cycles on vulnerable skin [41].
The protected weightbearing treatment period in a TCC
in our investigation was 20 ± 21 weeks for unilaterally af-
fected patients and 22 ± 29 weeks for bilaterally affected
subjects. Our average duration of treatment corresponds
to the findings of Armstrong et al with a period of 18.5 ±
10.6 weeks and Christensen et al of 20.1 ± 3 weeks [27].
However, they reported a re-casting of the unprotected
extremity for a mean of 11.2 weeks in cases of exacerba-
tion or recurrence of CN after reloading, i.e., upon initial
cast removal [27, 44]. Bates et al treated 34 patients with a
TCC and 12 individuals with a removable cast walker in
the presence of contraindications for a TCC for 11 (range:
8 to16.7) months, and 33% had to extend their treatment
period to a total duration of 20 (range, 15 to 21) (Bates M,
Petrova NL, Edmonds ME: How long does it take to pro-
gress from cast to shoes in the management of Charcot
osteoarthropathy? Diabetes Foot Study Group of the EASD,
unpublished) months due to recurrence of inflammation. In
our experience, a protected weightbearing regimen should
be maintained as long as signs of inflammation such as red-
ness and warmth are present. In the case of inconclusive
clinical signs, we recommend performing an MRI to ex-
clude residual inflammatory sites.
In our assessment, we found a shorter period until de-
finitive treatment was initiated (mean 5 months, range
1–65 months), compared to previously published inves-
tigations. Game et al reported a duration of treatment to
resolution (mobilized in orthotic or normal shoes) of
10 months (range 2–40 months) in a multicenter, web-
based observational study of 288 cases in the UK. Arm-
strong et al suggested a time to footwear of 7 ±
3.6 months in 55 patients with CN [44, 45].
Surgical treatment was performed in cases of chronic ul-
ceration or soft tissue infection to avoid amputation of the
limb. In our experience, open surgery on an inflamed CN
foot often ends in disastrous results due to infections, bone
resorption, or implant loosening [46]. Therefore, it is essen-
tial to find the correct timing for such an intervention.
Nevertheless, there are situations where stability of the
foot can only be achieved through operative interven-
tion. In these situations, the circular Ilizarov fixator is an
excellent treatment option because of the ability to cor-
rect multiplanar deformities [47]. Other investigators
provide early reconstructive surgery in patients with ad-
vanced instability of the foot. Intervention was associ-
ated with a benefit compared to secondary operations
after non-operative treatment concerning a stable, ulcer-
and infection free situation [22]. The goal in CN treat-
ment is a stable foot either by a multi-level arthrodesis
or a firm fibrosis, which can be fitted with a custom-
made shoe [23, 24]. El-Gafary et al treated 20 patients
with CN at Eichenholtz stage 2 and presence of joint
subluxations or deformities with repositioning and
stabilization by application of an Ilizarov frame with re-
stricted weightbearing [48]. They reported good clinical
outcomes with a time to arthrodesis of 18 weeks (range
15–20 weeks) [48]. However, pin site infections in these
situations were frequent (15 of 20 patients).
Our study has limitations. We had no measurements of
skin temperature, HbA1c, or body mass index at the onset
of disease or during the follow-up period. Also, the poten-
tial impact of wounds present at initiation of treatment on
the primary outcome of new ulcer incidence is not well
understood. Further limitations are the retrospective study
design and the lack of precise matching of groups. Al-
though our assessment included one of the largest sam-
ples available compared to other studies of CN, evaluation
of treatment regimens for this disease would benefit from
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larger, prospective trials with homogenous patient cohorts.
Nevertheless, our findings may assist in the decision mak-
ing and treatment planning for a CN foot.
Conclusion
In conclusion, protected weightbearing treatment in a
TCC is a valuable option for patients with acute CN, with
a significantly lower incidence of ulcerations compared to
an unprotected treatment. Larger population studies are
recommended to further support this observation.
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